Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 17/20 | 1.00 |
| ▸ | FNTB | P49356 | 15/20 | 1.00 |
| ▸ | PGGT1B | P53609 | 6/20 | 1.00 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Farnesyl Diphosphate SCHEMBL157143 | 1.00 | FNTA (1.00) | FNTAFNTBPGGT1BBTN3A1 | |
| SCHEMBL2506505 | 1.00 | FNTA (1.00) | FNTAFNTBPGGT1BBTN3A1 | |
| SCHEMBL15541984 | 1.00 | FNTA (1.00) | FNTAFNTBPGGT1BBTN3A1 | |
| SCHEMBL23802599 | 1.00 | FNTA (1.00) | FNTAFNTBPGGT1BBTN3A1 | |
| Farnesyl Diphosphate SCHEMBL4945165 | 1.00 | FNTA (1.00) | FNTAFNTBPGGT1BBTN3A1 | |
| SCHEMBL23610949 | 1.00 | FNTA (1.00) | FNTAFNTBPGGT1BBTN3A1 | |
| Farnesyl Diphosphate SCHEMBL5162539 | 1.00 | FNTA (1.00) | FNTAFNTBPGGT1BBTN3A1 | |
| SCHEMBL25272102 | 1.00 | FNTA (1.00) | FNTAFNTBPGGT1BBTN3A1 | |
| Farnesyl Diphosphate SCHEMBL20798083 | 1.00 | FNTA (1.00) | FNTAFNTBPGGT1BBTN3A1 | |
| Farnesyl Diphosphate SCHEMBL109441 | 1.00 | FNTA (1.00) | FNTAFNTBPGGT1BBTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220025419-A1 | N-GLYCOSYLATION OF PEPTIDES AND PROTEINS | GLYCOVAXYN AG (CH) | 2022-01-27 | — | — | US | disclosed |
| EP-3057975-B1 | N-GLYCOSYLATION OF PEPTIDES AND PROTEINS | UNIV OXFORD INNOVATION LTD (GB) | 2019-09-04 | — | — | EP | disclosed |
| US-20160257983-A1 | N-GLYCOSYLATION OF PEPTIDES AND PROTEINS | ISIS INNOVATION LIMITED (GB) | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220025419-A1 | N-GLYCOSYLATION OF PEPTIDES AND PROTEINS | PGLS, NGLY1, PTMS | FNTA 181/4885FNTB 42/4885PGGT1B 361/4885 |
| US-20160257983-A1 | N-GLYCOSYLATION OF PEPTIDES AND PROTEINS | PTMS, PGLS, PSPH | FNTA 215/4885FNTB 60/4885PGGT1B 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.